The 5-year survival rate of rectal NET patients with SSTR2 expression was significantly better than those without SSTR2 expression (98.5% vs. 92.6%, p = 0.006; Fig. 3a). This evidence concerns the gene SSTR2 and rectum neuroendocrine neoplasm.